Skip to content

Dexamethasone for Cardiac Surgery study

Dexamethasone for Cardiac Surgery study: a large, simple trial of dexamethasone versus placebo in patients undergoing cardiac surgery.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON19963
Enrollment
4500
Registered
2007-10-21
Start date
2006-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Cardiac surgery (Hartchirurgie)

Interventions

Administration of dexamethasone 1 mg/kg, or placebo.

Sponsors

UMC Utrecht, Division of Perioperative Care & Emergency Medicine (Prof.dr. C.J. Kalkman)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All types of cardiac surgery in which cardiopulmonary bypass is used.

Exclusion criteria

Exclusion criteria: 1. Age under 18 years; 2. Life-expectancy <6 months; 3. Emergency operations; 4. Re-operations within the same admission.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.

Secondary

MeasureTime frame
1. The occurrence of one or more major complications within the first year after surgery; 2. the separate components of the primary outcome measure, i.e. major complications in the first 30 days after surgery; 3. quality of life at 30 days and one year after surgery; 4. wound infection in the first 30 days after surgery; 5. use of anti-anginal drugs at 30 days after surgery; 6. atrial fibrillation in ICU; 7. highest serum glucose concentration in ICU; 8. use of inotropes on the first postoperative day; 9. highest body temperature in ICU; 10. time to extubation; 11. time to discharge from ICU; 12. time to discharge from hospital; 13. change in cognitive performance from before to 30 days after surgery (subsample of 400 patients); 14. serum glucose-values and insulin use in ICU (subsample of patients in the UMC Utrecht); 15. cost-effectiveness analysis.

Contacts

Public ContactJ.M Dieleman

PO Box 85500,

S.Dieleman@UMCUtrecht.nl+31 (0)30 2509677

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)